Interní Med. 2015; 17(4): 192-195

News and perspectives in insulin treatment

prof.MUDr.Martin Haluzík, DrSc.
III. interní klinika 1. LF UK a VFN, Praha

Insulin therapy is an inseparable part of the treatment of patients with type 1 diabetes and also of many patients with type 2 diabetes, in

particular those with longer disease duration. In many patients with type 2 diabetes, insulin therapy is often initiated later than optimal.

One of the reasons is suboptimal pharmacokinetics of the currently available insulins. This is why there is an intensive effort aiming at

the development of novel insulins with improved characteristics closer to physiological regulation of insulin secretion. The aim of this

paper is to summarize the current knowledge concerning new insulins that have been recently introduced or will be soon introduced

into the market. We will also discuss the perspectives of insulin therapy in the longer-term horizon including the efforts of development

of insulins with alternative route of administration.

Keywords: diabetes, insulin, insulin analogues, hypoglycemia, alternative options of insulin administration

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haluzík M. News and perspectives in insulin treatment. Interní Med. 2015;17(4):192-195.
Download citation

References

  1. Škrha J, et al. Diabetologie. 1. vydání. Praha: Galén 2009.
  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 2012; 35: 1364-1379. Go to original source... Go to PubMed...
  3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 2015; 38: 140-149. Go to original source... Go to PubMed...
  4. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760. Go to original source... Go to PubMed...
  5. Investigators TOT. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. The New England journal of medicine 2012.
  6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine 2008; 359: 1577-1589. Go to original source... Go to PubMed...
  7. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007; 57: 455-460. Go to original source...
  8. Simons WR, Vinod HD, Gerber RA, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes 2006; 114: 520-526. Go to original source... Go to PubMed...
  9. Baldeweg SE, Yudkin JS. Implications of the United Kingdom prospective diabetes study. Primary care 1999; 26: 809-827. Go to original source... Go to PubMed...
  10. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, obesity & metabolism 2005; 7: 56-64. Go to original source... Go to PubMed...
  11. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes care 2000; 23: 1130-1136. Go to original source... Go to PubMed...
  12. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, obesity & metabolism 2011; 13: 677-684. Go to original source... Go to PubMed...
  13. Zachariah S, Sheldon B, Shojaee-Moradie F, et al. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes care 2011; 34: 1487-1491. Go to original source... Go to PubMed...
  14. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. The American journal of medicine 2004; 117: 291-296. Go to original source... Go to PubMed...
  15. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes care 1993; 16(Suppl 3): 90-100. Go to original source... Go to PubMed...
  16. Mathieu C. Can we reduce hypoglycaemia with insulin detemir? International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2004; 28(Suppl 2): S35-40. Go to original source... Go to PubMed...
  17. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63: 1743-1778. Go to original source... Go to PubMed...
  18. Gough SC, Harris S, Woo V, Davies M. Insulin degludec: Overview of a novel ultra long-acting basal insulin. Diabetes, obesity & metabolism 2012. Go to original source... Go to PubMed...
  19. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharmaceutical research 2012; 29: 2104-2114. Go to original source... Go to PubMed...
  20. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes, obesity & metabolism 2012; 14: 944-950. Go to original source... Go to PubMed...
  21. Goldman-Levine JD, Patel DK, Schnee DM. Insulin degludec: a novel basal insulin analogue. The Annals of pharmacotherapy 2013; 47: 269-277. Go to original source... Go to PubMed...
  22. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. The Journal of clinical endocrinology and metabolism 2013; 98: 1154-1162. Go to original source... Go to PubMed...
  23. Sutton G, Minguet J, Ferrero C, Bramlage P. U300, a novel long-acting insulin formulation. Expert opinion on biological therapy 2014; 14: 1849-1860. Go to original source... Go to PubMed...
  24. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes care 2012; 35: 2140-2147. Go to original source... Go to PubMed...
  25. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes care 2013; 36: 522-528. Go to original source... Go to PubMed...
  26. Hill J. New insulin analogues and their impact on diabetes care. Br J Community Nurs 2003; 8: 515-518. Go to original source... Go to PubMed...
  27. Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. The Annals of pharmacotherapy 2015; 49: 99-106. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.